Pemvidutide Guide
Altimmune
Complete guide to Pemvidutide (ALT-801 / AZD9550) — Altimmune
What Is Pemvidutide?
Pemvidutide (development names ALT-801 and AZD9550) is being developed by Altimmune in partnership with AstraZeneca. It is a balanced dual agonist of the GLP-1 receptor and the glucagon receptor (GCGR), administered as a once-weekly subcutaneous injection.
The GLP-1 component suppresses appetite and slows gastric emptying — the same mechanism as semaglutide (Ozempic/Wegovy). The glucagon component adds a distinct thermogenic effect: it increases metabolic rate, enhances fat oxidation, and promotes fat clearance from the liver. Together, these two pathways produce weight loss that is both significant and qualitatively different from pure GLP-1 monotherapy.
Why it matters: The glucagon component drives fat loss preferentially, which is why DEXA scan data from MOMENTUM showed pemvidutide users retaining lean muscle mass at rates superior to semaglutide. For patients focused on body composition — not just the number on the scale — this distinction is critical.
MOMENTUM Phase 2b Trial Results
The Dual Mechanism: GLP-1 + Glucagon
Muscle Preservation: Why Pemvidutide Is Different
MASH / Liver Disease Potential
Beyond weight loss and muscle preservation, pemvidutide is being studied for MASH (metabolic dysfunction-associated steatohepatitis) — formerly called NASH. This is the progressive form of fatty liver disease that can advance to cirrhosis and liver failure.
The glucagon receptor plays a well-established role in hepatic (liver) fat metabolism. GCGR activation directly reduces liver fat accumulation by promoting fat oxidation in hepatocytes and reducing fat synthesis. This same mechanism that spares muscle also clears fat from the liver.
Other GLP-1/glucagon dual agonists like Survodutide have shown remarkable MASH results (83% resolution in Phase 2). Pemvidutide's similar mechanism positions it as a credible candidate for liver disease treatment — though liver-specific Phase 2/3 data is still maturing.
Development Timeline & ADVANCE Phase 3
Vital Protocol FAQs
Guide FAQs
Complete guide to Pemvidutide (ALT-801 / AZD9550) — Altimmune
Yes. Shotlee supports tracking Pemvidutide doses, side effects, and health metrics. It is free to use.
PubMed, ClinicalTrials.gov, and the FDA website are the most reliable sources for current Pemvidutide research and regulatory updates. Peer-reviewed journals including the New England Journal of Medicine, The Lancet, and JAMA publish the most impactful clinical trial results. This guide is updated regularly to reflect the latest available evidence. Use Shotlee to track your personal protocol outcomes alongside the published research.
Before starting Pemvidutide, establish baseline measurements including body weight, waist circumference, blood pressure, and relevant lab work with your healthcare provider. Download Shotlee and begin logging your baseline metrics at least one week before starting treatment. This pre-treatment data provides the comparison point needed to objectively evaluate your treatment response over time. Additionally, discuss potential side effects and management strategies with your prescriber so you are prepared for the initial adaptation phase.
Evidence-based lifestyle modifications that complement Pemvidutide protocols include: maintaining adequate protein intake (1.2-1.6g per kg body weight per day) to preserve lean mass, performing resistance training two to three times per week, staying well hydrated with at least eight glasses of water daily, prioritizing seven to nine hours of quality sleep, managing stress through regular physical activity or mindfulness practices, and eating smaller more frequent meals during dose titration phases. Track these lifestyle factors alongside your Pemvidutide data in Shotlee to identify which combinations drive your best results.
Track Your Pemvidutide Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.